Profile

Rhythm Biotherapeutics develops first-in-class, heart-derived exosome therapeutics to prevent atrial fibrillation. Its patented GMP process produces natural vesicles enriched with anti-inflammatory and anti-fibrotic cargo. Supported by strong preclinical efficacy in large-animal models, it is advancing toward regulatory submission for a Phase 1 trial in 2026. Its technology addresses a major unmet need, offering safer, targeted prevention of post-operative atrial fibrillation with potential expansion into broader arrhythmia and cardiovascular indications.

Rhythm Biotherapeutics Inc. logo

Website

rthm.bio

Contact


Event details

Date: November 3 - 5, 2025

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences

Participants

22 in total